Peer-influenced content. Sources you trust. No registration required. This is HCN.
Medgadget
Getting a handle on the biochemical processes that govern how food is broken down and used within the body can be a daunting task for many, and even for those who understand it, monitoring with technology isn’t always possible. This is where Levels come into play. An instant metabolic analysis just a few hours after eating is only the beginning of the Levels experience; the app focuses on four major blood glucose levers in a gamified experience: diet, exercise, stress, and sleep. Dr. Lauren Kelley-Chew, Levels’ Head of Clinical Product, discusses all of this and more.
Cardiology April 5th 2023
Consultant360
The study was conducted while GLP-1 RAs and SGLT-2 inhibitors were still considered second-line therapies; however, in a 2022 Consensus Report, the American Diabetes Association and the European Association for the Study of Diabetes recommended these medications as first-line therapy for people with type 2 diabetes who have or are at high risk of certain complications such as heart failure, CKD, and atherosclerotic cardiovascular disease (ASCVD). Are the medications’ price tag keeping people away?
Endocrinology, Diabetes, Metabolism April 5th 2023
ACP Internist
Whether prescribing them for diabetes or weight loss, what factors should you consider when choosing among the seven approved GLP-1 agonist formulations? This concise review highlights the variables.
Endocrinology, Diabetes, Metabolism March 15th 2023
Annals of Internal Medicine
The results of these trials show that vitamin D reduced the risk of diabetes progression by 3% to 18% after three years, with serum 25-hydroxy D levels of at least 125 nmol/L showing the greatest benefit. Vitamin D was also associated with a 30% increase in the likelihood of returning to normal glucose regulation.
Endocrinology, Diabetes, Metabolism February 23rd 2023
MDLinx
This summary of a January 2023 JACC article highlights the study finding that rosuvastatin was “vastly superior to… any of the six supplements studied in the trial.” The study compared rosuvastatin to cinnamon, garlic, turmeric, red yeast rice, fish oil, and plant sterols. Rosuvastatin yielded a reduction in cholesterol of nearly 38 percent in just 28 days. The supplements had little to no effect but were significantly more costly than the statin.
Cardiology February 8th 2023
The New England Journal of Medicine
Versus placebo, pemafibrate yielded a more than 25% greater reduction in triglycerides, VLDL, remnant cholesterol, and apolipoprotein C-III in patients with type 2 diabetes. However, there was no reduction versus placebo in MI, ischemic stroke, need for coronary revascularization, or CV death.
Cardiology December 7th 2022